Lucatumumab Uses, Dosage, Side Effects and more
| Attribute | Details |
|---|---|
| Trade Name | Lucatumumab |
| Generic | Lucatumumab |
| Lucatumumab Other Names | Lucatumumab |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
Uses
Investigated for use/treatment in leukemia (lymphoid), multiple myeloma, and lymphoma (unspecified).
How Lucatumumab works
HCD122 is a fully human, antagonist antibody that targets the CD40 antigen. HCD122 binds to tumor cells that express CD40 and antagonizes (prevents) CD40 ligand-mediated growth and survival of malignant B cells. Based on preclinical data, HCD122 also induces antibody-dependent cellular cytotoxicity (ADCC), killing CD40 expressing tumor cells by immune effector cells. This dual mechanism of action makes HCD122 a drug candidate with potential for the treatment of B-cell malignancies.
